Citadel Advisors’s BioLife Solutions BLFS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.66M | Buy |
244,172
+146,859
| +151% | +$3.25M | ﹤0.01% | 4460 |
|
|
2025
Q4 | $2.35M | Sell |
97,313
-41,171
| -30% | -$1.08M | ﹤0.01% | 5609 |
|
|
2025
Q3 | $3.53M | Sell |
138,484
-281,753
| -67% | -$6.68M | ﹤0.01% | 4993 |
|
|
2025
Q2 | $9.05M | Buy |
420,237
+297,435
| +242% | +$6.7M | ﹤0.01% | 3170 |
|
|
2025
Q1 | $2.8M | Sell |
122,802
-166,784
| -58% | -$4.39M | ﹤0.01% | 4885 |
|
|
2024
Q4 | $7.52M | Buy |
289,586
+24,089
| +9% | +$599K | ﹤0.01% | 3346 |
|
|
2024
Q3 | $6.65M | Buy |
265,497
+167,686
| +171% | +$3.96M | ﹤0.01% | 3495 |
|
|
2024
Q2 | $2.1M | Sell |
97,811
-464,235
| -83% | -$9.01M | ﹤0.01% | 5215 |
|
|
2024
Q1 | $10.4M | Buy |
562,046
+6,085
| +1% | +$106K | ﹤0.01% | 2904 |
|
|
2023
Q4 | $9.03M | Sell |
555,961
-53,002
| -9% | -$676K | ﹤0.01% | 2987 |
|
|
2023
Q3 | $8.41M | Buy |
608,963
+608,788
| +347,879% | +$9.59M | ﹤0.01% | 2903 |
|
|
2023
Q2 | $3.87K | Sell |
175
-31,339
| -99% | -$660K | ﹤0.01% | 13650 |
|
|
2023
Q1 | $685K | Sell |
31,514
-20,047
| -39% | -$451K | ﹤0.01% | 7623 |
|
|
2022
Q4 | $938K | Buy |
51,561
+30,968
| +150% | +$639K | ﹤0.01% | 6939 |
|
|
2022
Q3 | $468K | Sell |
20,593
-43,252
| -68% | -$925K | ﹤0.01% | 8606 |
|
|
2022
Q2 | $881K | Sell |
63,845
-69,967
| -52% | -$1.03M | ﹤0.01% | 7314 |
|
|
2022
Q1 | $3.04M | Buy |
133,812
+24,701
| +23% | +$650K | ﹤0.01% | 5143 |
|
|
2021
Q4 | $4.07M | Buy |
109,111
+62,364
| +133% | +$2.68M | ﹤0.01% | 4713 |
|
|
2021
Q3 | $1.98M | Buy |
+46,747
| New | +$2.25M | ﹤0.01% | 6370 |
|
|
2021
Q2 | – | Sell |
-61,014
| Closed | -$2.15M | – | 13677 |
|
|
2021
Q1 | $2.2M | Buy |
61,014
+22,324
| +58% | +$883K | ﹤0.01% | 6171 |
|
|
2020
Q4 | $1.54M | Buy |
+38,690
| New | +$1.32M | ﹤0.01% | 5915 |
|
|
2020
Q3 | – | Sell |
-25,122
| Closed | -$411K | – | 10076 |
|
|
2020
Q2 | $411K | Buy |
25,122
+12,495
| +99% | +$172K | ﹤0.01% | 7418 |
|
|
2020
Q1 | $120K | Buy |
+12,627
| New | +$173K | ﹤0.01% | 8489 |
|
|
2019
Q3 | – | Sell |
-41,824
| Closed | -$709K | – | 9160 |
|
|
2019
Q2 | $709K | Buy |
+41,824
| New | +$729K | ﹤0.01% | 6257 |
|
|
2018
Q3 | – | Sell |
-16,989
| Closed | -$194K | – | 9204 |
|
|
2018
Q2 | $194K | Buy |
16,989
+5,946
| +54% | +$54.1K | ﹤0.01% | 7908 |
|
|
2018
Q1 | $56K | Buy |
+11,043
| New | +$59.8K | ﹤0.01% | 7900 |
|
|
2017
Q1 | – | Sell |
-16,710
| Closed | -$27K | – | 7436 |
|
|
2016
Q4 | $27K | Buy |
16,710
+5,663
| +51% | +$9.15K | ﹤0.01% | 7016 |
|
|
2016
Q3 | $20K | Sell |
11,047
-7,738
| -41% | -$14.7K | ﹤0.01% | 7038 |
|
|
2016
Q2 | $30K | Buy |
18,785
+8,533
| +83% | +$14.6K | ﹤0.01% | 6519 |
|
|
2016
Q1 | $19K | Buy |
+10,252
| New | +$18.9K | ﹤0.01% | 6475 |
|
|
2015
Q2 | – | Sell |
-16,133
| Closed | -$26K | – | 8724 |
|
|
2015
Q1 | $26K | Buy |
+16,133
| New | +$30.2K | ﹤0.01% | 7755 |
|
Other funds holding BLFS
CC
VCM
FAM
Citadel Advisors's BLFS Position: Q1 2026 in Review
Citadel Advisors increased its BioLife Solutions (BLFS) stake by 151% in Q1 2026, buying an estimated $3.25M and bringing the position to 244,172 shares worth $4.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4460.
Citadel Advisors first reported a position in BLFS in Q1 2015 and has held it in 31 quarters since. The position peaked at $10.4M in Q1 2024. 187 funds tracked by Wall St. Rank hold BLFS as of Q1 2026.
- Citadel Advisors held 244,172 shares of BioLife Solutions worth $4.66M as of Q1 2026.
- Citadel Advisors bought 146,859 BioLife Solutions shares in Q1 2026, an estimated $3.25M.
- BioLife Solutions made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4460 holding.
- Citadel Advisors first reported a position in BioLife Solutions in Q1 2015 and has held it in 31 quarters since.
- Citadel Advisors's BioLife Solutions position peaked at $10.4M in Q1 2024.
- 187 funds tracked by Wall St. Rank held BioLife Solutions as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.